Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
15.10
+0.55 (3.78%)
May 18, 2026, 4:00 PM EDT - Market closed
Caris Life Sciences Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Caris Life Sciences stock has a consensus rating of "Strong Buy" and an average price target of $28. The average 1-year stock price forecast is 85.43% higher than the current stock price, while the lowest is $21 (+39.07%) and the highest is $36 (+138.41%).
Price Target: $28 (+85.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Caris Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 5 | 5 |
| Buy | 3 | 3 | 4 | 4 | 4 | 5 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 9 | 9 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $35 → $28 | Strong Buy | Maintains | $35 → $28 | +85.43% | May 8, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $35 → $30 | Buy | Maintains | $35 → $30 | +98.68% | May 8, 2026 |
| BTIG | BTIG | Strong Buy Maintains $38 → $32 | Strong Buy | Maintains | $38 → $32 | +111.92% | May 8, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +85.43% | Apr 13, 2026 |
| Piper Sandler | Piper Sandler | Hold Initiates $21 | Hold | Initiates | $21 | +39.07% | Apr 10, 2026 |
Financial Forecast
Revenue This Year
1.02B
from 812.03M
Increased by 25.24%
Revenue Next Year
1.24B
from 1.02B
Increased by 22.32%
EPS This Year
0.15
from -3.22
EPS Next Year
0.36
from 0.15
Increased by 142.22%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.1B | 1.4B | ||||||
| Avg | 1.0B | 1.2B | ||||||
| Low | 980.0M | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 30.9% | 33.2% | ||||||
| Avg | 25.2% | 22.3% | ||||||
| Low | 20.7% | 13.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.56 | 0.56 | |||
| Avg | 0.15 | 0.36 | |||
| Low | 0.02 | 0.14 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 272.6% | |||
| Avg | - | 142.2% | |||
| Low | - | -8.1% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.